Tonabacase (LSVT-1701)

Phase 2Small molecule

LLysovant

Tonabacase (LSVT-1701) is one of 15 small molecule programs targeting Endocarditis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EndocarditisActive, not recruiting

EndocarditisPhase 2

Active, not recruiting

Competition

Competitive Landscape

40 competitors in Endocarditis

#DrugCompanyPhaseTrials

Zyvox

Pfizer

Approved

1 2

Cubicin

BBaxter Healthcare Corporation

Approved

2 3

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

2 4

Gantanol

CConrado Roberto Hoffmann Filho

Approved

1 5

Rocephin

CConrado Roberto Hoffmann Filho

Rifadin

1 7

Ceclor

Eli Lilly

Approved

1 8

Pathocil

WWyeth-Lederle Vaccines

Approved

1 9

Levaquin

WWim Janssens

Phase 3

2 10

Rifampicin

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endocarditis1 trial

ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis

Withdrawn·LLysovant·Phase 2·NCT05329168

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tonabacase (LSVT-1701). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tonabacase (LSVT-1701) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tonabacase (LSVT-1701). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lysovant company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLysovant

Tonabacase (LSVT-1701)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endocarditis1 trial

References

Drug Info

Quick Facts

Related News